Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

Journal of Clinical Oncology

Volumn 20, Issue 19, 2002, Pages 4074-4082

  Tan, Antoinette R ^a   Headlee, Donna ^a   Messmann, Richard ^a   Sausville, Edward A ^a   Arbuck, Susan G ^a   Murgo, Anthony J ^a   Melillo, Giovanni ^a   Zhai, Suoping ^a   Figg, William D ^a   Swain, Sandra M ^a   Senderowicz, Adrian M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIDIARRHEAL AGENT; BISMUTH SALICYLATE; COLESTYRAMINE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; GRANISETRON; LOPERAMIDE; METOCLOPRAMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER PAIN; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFLAMMATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TUMOR THROMBUS;

EID: 0036789539     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.01.043     Document Type: Article

References (37)

1. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
2. Senderowicz AM, Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92:376-387, 2000
3. Kaur G. Stetler-Stevenson M, Sebers S, et al: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84:1736-1740, 1992
4. Worland PJ, Kaur G, Stetler-Stevenson M, et al: Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: Correlation with decreased HI kinase activity. Biochem Pharmacol 46:1831-1840, 1993
5. Losiewicz MD, Carlson BA, Kaur G, et al: Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201:589-595, 1994
6. Carlson BA, Dubay MM, Sausville EA, et al: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973-2978, 1996
7. De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, et al: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A 93:2735-2740, 1996
8. Carlson B, Lahusen T, Singh S, et al: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59:4634-4641, 1999
9. Patel V, Senderowicz AM, Pinto D, et al: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 102:1674-1681, 1998
10. Bible KC, Kaufmann SH: Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856-4861, 1996
11. Konig A, Schwartz GK, Mohammad RM, et al: The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90:4307-4312, 1997
12. Arguello F, Alexander M, Sterry JA, et al: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91:2482-2490, 1998
13. Byrd JC, Shinn C, Waselenko JK, et al: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92:3804-3816, 1998
14. Parker BW, Kaur G, Nieves-Neira W, et al: Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91:458-465, 1998
15. Schrump DS, Matthews W, Chen GA, et al: Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res 4:2885-2890, 1998
16. Chien M, Astumian M, Liebowitz D, et al: In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol 44:81-87, 1999
17. Achenbach TV, Muller R, Slater EP: Bcl-2 independence of flavopiridol-induced apoptosis: Mitochondrial depolarization in the absence of cytochrome c release. J Biol Chem 275:32089-32097, 2000
18. Kitada S, Zapata JM, Andreeff M, et al: Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96:393-397, 2000
19. Pepper C, Thomas A, Hoy T, et al: Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 114:70-77, 2001
20. Brusselbach S, Nettelbeck DM, Sedlacek HH, et al: Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 77:146-152, 1998
21. Kerr JS, Wexler RS, Mousa SA, et al: Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res 19:959-968, 1999
22. Melillo G, Sausville EA, Cloud K, et al: Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 59:5433-5437, 1999
23. Sedlacek HH, Czech J, Naik R, et al: Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9:1143-1168, 1996
24. Senderowicz AM, Headlee D, Stinson SF, et al: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986-2999, 1998
25. Thomas J, Cleary J, Tutsch K, et al: Phase I clinical and pharmacokinetic trial of flavopiridol. Proc Am Assoc Cancer Res 38:222, 1997 (abstr 1496)
26. Stadler WM, Vogelzang NJ, Amato R, et al: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 18:371-375, 2000
27. Schwartz GK, Ilson D, Saltz L, et al: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19:1985-1992, 2001
28. Shapiro GI, Supko JG, Patterson A, et al: A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7:1590-1599, 2001
29. Bennett P, Mani S, O'Reilly E, et al: Phase II trial of flavopiridol in metastatic colorectal cancer: Preliminary results. Proc Am Soc Clin Oncol 18:277a, 1999 (abstr 1065)
30. World Health Organization: Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979, Offset Publication No 48
31. Gray NS, Wodicka L, Thunnissen AM, et al: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533-538, 1998
32. Lilja L, Yang SN, Webb DL, et al: Cyclin-dependent kinase 5 promotes insulin exocytosis. J Biol Chem 276:34199-34205, 2001
33. Jager W, Zembsch B, Wolschann P, et al: Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci 62:1861-1873, 1998
34. Innocenti F, Stadler WM, Iyer L, et al: Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res 6:3400-3405, 2000
35. Hagenauer B, Salamon A, Thalhammer T, et al: In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: Involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug Metab Dispos 29:407-414, 2001
36. Connors JM, Kouroukis C, Belch A, et al: Flavopiridol for mantle cell lymphoma: Moderate activity and frequent disease stabilization. Blood 98:807a, 2001 (abstr 3355)
37. Schwartz GK, O'Reilly E, Ilson D, et al: Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 20:2157-2170, 2002